The cardiac amyloidosis market is primarily driven by increasing prevalence of cardiac amyloidosis and growing research investments. Cardiac amyloidosis is a rare disease caused by accumulation of abnormal amyloid protein in the heart muscle. The buildup of amyloid protein in the heart weakens and stiffens the heart which leads to heart failure over time if left untreated. Currently, there are limited treatment options available for cardiac amyloidosis such as chemotherapy, stem cell transplant, drugs to reduce amyloid production and certain lifestyle changes.
The Global Cardiac Amyloidosis Market is estimated to be valued at USD 6.12 Bn in 2024 and is expected to reach USD 11.45 Bn by 2031, growing at a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031.
Key Takeaways
- Key players operating in the cardiac amyloidosis market are copyright, Alnylam Pharmaceuticals, Prothena, Ionis Pharmaceuticals and Samarth Pharma.
- Increasing prevalence of cardiac diseases and rising awareness about cardiac amyloidosis is driving the growth of the Cardiac Amyloidosis Market. More than 200,000 new cases are diagnosed each year in the US alone.
- Continuous research and development is leading to development of novel therapeutic approaches such as gene silencing therapy, immunotherapy and stem cell therapy which is expected to transform the treatment landscape.
Market Trends
- Gene therapy is emerging as a promising treatment option for cardiac amyloidosis. Companies are developing RNAi therapeutics targeting amyloid protein production which has shown positive results in clinical trials.
- Combination therapy approaches combining drugs, stem cell transplants and lifestyle modifications are being explored to enhance treatment efficacy.
Market Opportunities
- Asia Pacific region presents lucrative opportunities for cardiac amyloidosis drug manufacturers due to growing healthcare spending and increasing awareness.
- Support from private and government funding for research on rare diseases is encouraging pharmaceutical companies to develop novel drugs for cardiac amyloidosis.
Impact of COVID-19 on Cardiac Amyloidosis Market Growth
The COVID-19 pandemic has significantly impacted the growth of the cardiac amyloidosis market. During the initial lockdown stages in 2020, patients postponed non-emergency medical procedures and appointments due to fear of contracting the infection at hospitals. This led to delay in diagnoses of new cardiac amyloidosis cases. Moreover, drug manufacturers faced disruptions in supply chains affecting the production and supply of supportive care drugs for cardiac amyloidosis patients.
As lockdowns were lifted gradually, hospital visits resumed but under strict safety protocols. This led to a backlog of pending cardiac amyloidosis cases that required diagnosis and treatment. The demand for diagnostic tests like echocardiogram and cardiac MRI saw a rise. At the same time, pharmaceutical companies stepped up production while focusing on employee safety to meet the increasing demand for drugs. Telecardiology also emerged as an effective tool for managing stable cardiac amyloidosis patients remotely.
With the development of COVID-19 vaccines, the situation is returning to pre-pandemic levels. However, drug developers are focusing on new targeted therapies and combinations to provide more effective treatment options. Meanwhile, healthcare systems are better prepared to handle future outbreaks while minimizing impact on management of chronic conditions like cardiac amyloidosis.
Geographical Regions with High Cardiac Amyloidosis Market Value
North America dominates the global cardiac amyloidosis market owing to the high healthcare expenditure and presence of major market players in the US. According to sources, the US accounted for over 35% of the global market share in terms of revenue. This is attributed to the rising prevalence of AL amyloidosis along with greater awareness about the condition.
Western Europe is another prominent regional market led by Germany, France and the UK. Extensive research funding for rare diseases like cardiac amyloidosis along with supportive government reimbursement policies drive market growth. Additionally, Asia Pacific is projected as the fastest growing region in the long run with China and India emerging as lucrative countries. This can be accredited to improving access to healthcare facilities and increasing focus of global companies on emerging Asian markets.
Get more insights on : Cardiac Amyloidosis Market
Get this Report in Japanese Language: 心臓アミロイドーシス市場
Get this Report in Korean Language: 심장 아밀로이드증 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)